{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:04:54Z","timestamp":1792695894412,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2007,12,23]],"date-time":"2007-12-23T00:00:00Z","timestamp":1198368000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2008,4]]},"DOI":"10.1007\/s00213-007-1030-6","type":"journal-article","created":{"date-parts":[[2007,12,22]],"date-time":"2007-12-22T05:22:35Z","timestamp":1198300955000},"page":"279-293","source":"Crossref","is-referenced-by-count":47,"title":["The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson\u2019s disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram"],"prefix":"10.1007","volume":"197","author":[{"given":"Wei-Li","family":"Kuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Wei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger A.","family":"Barker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,12,23]]},"reference":[{"key":"1030_CR1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/ana.20296","volume":"57","author":"I Aubert","year":"2005","unstructured":"Aubert I, Guigoni C, Hakansson K, Li Q, Dovero S, Barthe N, Bioulac BH, Gross CE, Fisone G, Bloch B, Bezard E (2005) Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann Neurol 57:17\u201326","journal-title":"Ann Neurol"},{"key":"1030_CR2","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/00007691-200404000-00014","volume":"26","author":"P Baumann","year":"2004","unstructured":"Baumann P, Hiemke C, Ulrich S, Gaertner I, Rao ML, Eckermann G (2004) Therapeutic monitoring of psychotropic drugs: an outline of the AGNP-TDM expert group consensus guideline. The Drug Monitor 26:167\u201370","journal-title":"The Drug Monitor"},{"key":"1030_CR3","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/35086062","volume":"2","author":"E Bezard","year":"2001","unstructured":"Bezard E, Brotchie JM, Gross CE (2001) Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev 2:577\u201388","journal-title":"Nat Rev"},{"key":"1030_CR4","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/45251","volume":"402","author":"JA Bibb","year":"1999","unstructured":"Bibb JA, Snyder GL, Nishi A, Yan Z, Meijer L, Fienberg AA, Tsai LH, Kwon YT, Girault JA, Czernik AJ, Huganir RL, Hemmings HC Jr., Nairn AC, Greengard P (1999) Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons. Nature 402:669\u201371","journal-title":"Nature"},{"key":"1030_CR5","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1212\/WNL.57.10.1829","volume":"57","author":"F Bibbiani","year":"2001","unstructured":"Bibbiani F, Oh JD, Chase TN (2001) Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology 57:1829\u201334","journal-title":"Neurology"},{"key":"1030_CR6","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0166-4328(02)00018-9","volume":"133","author":"P Boguszewski","year":"2002","unstructured":"Boguszewski P, Zagrodzka J (2002) Emotional changes related to age in rats - a behavioral analysis. Behav Brain Res 133:323\u2013332","journal-title":"Behav Brain Res"},{"key":"1030_CR7","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0028-3908(94)90099-X","volume":"33","author":"F Bolanos Jimenez","year":"1994","unstructured":"Bolanos Jimenez F, Manhaes de Castro R, Fillion G (1994) Effect of chronic antidepressant treatment on 5-HT1B presynaptic heteroreceptors inhibiting acetylcholine release. Neuropharmacology 33:77\u201381","journal-title":"Neuropharmacology"},{"key":"1030_CR8","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/00002826-199402000-00008","volume":"17","author":"V Bonifati","year":"1994","unstructured":"Bonifati V, Fabrizio E, Cipriani R, Vanacore N, Meco G (1994) Buspirone in levodopa-induced dyskinesias. Clin Neuropharmacol 17:73\u201382","journal-title":"Clin Neuropharmacol"},{"issue":"Pt 7","key":"1030_CR9","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1093\/brain\/awm082","volume":"130","author":"M Carta","year":"2007","unstructured":"Carta M, Carlsson T, Kirik D, Bj\u00f6rklund A (2007) Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 130(Pt 7):1819\u20131833","journal-title":"Brain"},{"key":"1030_CR10","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000054683","volume":"74","author":"WJ Cassano Jr","year":"2001","unstructured":"Cassano WJ Jr, D\u2019Mello AP (2001) Acute stress-induced facilitation of the hypothalamic-pituitary-adrenal axis: evidence for the roles of stressor duration and serotonin. Neuroendocrinology 74:167\u2013177","journal-title":"Neuroendocrinology"},{"key":"1030_CR11","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1212\/01.WNL.0000161841.41885.80","volume":"64","author":"KA Chung","year":"2005","unstructured":"Chung KA, Carlson NE, Nutt JG (2005) Short-term paroxetine treatment does not alter the motor response to levodopa in PD. Neurology 64:1797\u20138","journal-title":"Neurology"},{"key":"1030_CR12","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0091-3057(94)90472-3","volume":"49","author":"APM Cruz","year":"1994","unstructured":"Cruz APM, Frei F, Graeff FG (1994) Ethopharmacological analysis of rat behaviour on the elevated plus-maze. Pharmacol Biochem Behav 49:171\u2013176","journal-title":"Pharmacol Biochem Behav"},{"key":"1030_CR13","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.brainres.2006.10.062","volume":"1128","author":"M Benedetto Di","year":"2007","unstructured":"Di Benedetto M, D\u2019Addario C, Candeletti S, Romualdi P (2007) Alterations of CREB and DARPP-32 phosphorylation following cocaine and monoaminergic uptake inhibitors. Brain Research 1128:33\u201339","journal-title":"Brain Research"},{"key":"1030_CR14","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1212\/WNL.45.10.1855","volume":"45","author":"F Durif","year":"1995","unstructured":"Durif F, Vidailhet M, Bonnet AM, Blin J, Aqid Y (1995) Levodopa-induced dyskinesias are improved by fluoxetine. Neurology 45:1855\u20131858","journal-title":"Neurology"},{"key":"1030_CR15","doi-asserted-by":"crossref","first-page":"4810","DOI":"10.1523\/JNEUROSCI.16-15-04810.1996","volume":"16","author":"SE File","year":"1996","unstructured":"File SE, Gonzalez LE, Andrews N (1996) Comparative study of pre- and postsynaptic 5HT1A receptor modulation of anxiety in two ethological animal tests. J Neurosci 16:4810\u20134815","journal-title":"J Neurosci"},{"key":"1030_CR16","first-page":"469","volume":"43","author":"RW Fuller","year":"1986","unstructured":"Fuller RW (1986) Biochemical pharmacology of the serotonin system. Adv Neurol 43:469\u2013480","journal-title":"Adv Neurol"},{"issue":"2","key":"1030_CR17","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/mds.21226","volume":"22","author":"CG Goetz","year":"2007","unstructured":"Goetz CG, Damier P, Hicking C, Laska E, Muller T, Olanow CW, Rascol O, Russ H (2007) Sarizotan as a treatment for dyskinesias in Parkinson\u2019s disease: a double-blind placebo-controlled trial. Mov Disord 22(2):179\u2013186","journal-title":"Mov Disord"},{"key":"1030_CR18","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/BF02245224","volume":"113","author":"G Griebel","year":"1994","unstructured":"Griebel G, Moreau JL, Jenck F, Misslin R, Martin JR (1994) Acute and chronic treatment with 5-HT reuptake inhibitors differentially modulate emotional responses in anxiety models in rodents. Psychopharmacology 113:463\u2013470","journal-title":"Psychopharmacology"},{"key":"1030_CR19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0166-4328(02)00089-X","volume":"136","author":"YJ Ho","year":"2002","unstructured":"Ho YJ, Eichendorff J, Schwarting RK (2002) Individual response profiles of male Wistar rats in animal models for anxiety and depression. Behav Brain Res 136:1\u201312","journal-title":"Behav Brain Res"},{"key":"1030_CR20","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0091-3057(95)02126-4","volume":"54","author":"S Hogg","year":"1996","unstructured":"Hogg S (1996) A review of the validity and variability of the elevated plus-maze as an animal model of anxiety. Pharmacol Biochem Behav 54:21\u201330","journal-title":"Pharmacol Biochem Behav"},{"key":"1030_CR21","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/0006-8993(92)90914-U","volume":"584","author":"R Invernizzi","year":"1992","unstructured":"Invernizzi R, Belli S, Samanin R (1992) Citalopram\u2019s ability to increase the extracellular concentrations of serotonin in the dorsal raphe prevents the drug\u2019s effect in the frontal cortex. Brain Res 584:322\u2013234","journal-title":"Brain Res"},{"key":"1030_CR22","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1046\/j.1471-4159.2001.00184.x","volume":"76","author":"K Kannari","year":"2001","unstructured":"Kannari K, Yamato H, Shen H, Tomiyama M, Suda T, Matsunaga M (2001) Activation of 5-HT1A but not 5-HT1B receptors attenuates an increase in extracellular dopamine derived from exogenously administered L-DOPA in the striatum with nigrostriatal denervation. J Neurochem 76:1346\u20131353","journal-title":"J Neurochem"},{"key":"1030_CR23","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00228-006-0101-7","volume":"62","author":"S Krosser","year":"2006","unstructured":"Krosser S, Neugebauer R, Dolgos H, Fluck M, Rost KL, Kosar A (2006) Investigation of sarizotan\u2019s impact on the pharmacokinetics of probe drugs for major cytochrome P450 isoenzymes: a combined cocktail trial. Eur J Clin Pharmacol 62:277\u2013284","journal-title":"Eur J Clin Pharmacol"},{"key":"1030_CR24","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.nbd.2006.11.001","volume":"25","author":"WL Kuan","year":"2007","unstructured":"Kuan WL, Lin R, Tyers P, Barker RA (2007) The importance of A9 dopaminergic neurons in mediating the functional benefits of fetal ventral mesencephalon transplants and levodopa-induced dyskinesias. Neurobiol Dis 25:594\u2013608","journal-title":"Neurobiol Dis"},{"key":"1030_CR25","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1093\/brain\/123.7.1365","volume":"123","author":"CS Lee","year":"2000","unstructured":"Lee CS, Cenci MA, Schulzer M, Bjorklund A (2000) Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson\u2019s disease. Brain 123:1365\u20131379","journal-title":"Brain"},{"key":"1030_CR26","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/00002826-199708000-00002","volume":"20","author":"E Miyawaki","year":"1997","unstructured":"Miyawaki E, Meah Y, Koller WC (1997) Serotonin, dopamine, and motor effects in Parkinson\u2019s disease. Clin Neuropharmacol 20:300\u2013310","journal-title":"Clin Neuropharmacol"},{"key":"1030_CR27","volume-title":"The Rat Brain in Stereotaxic Coordinates","author":"G Paxinos","year":"1982","unstructured":"Paxinos G, Watson C (1982) The Rat Brain in Stereotaxic Coordinates. Academic Press, Academic Press"},{"key":"1030_CR28","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/syn.890190309","volume":"19","author":"AM Persico","year":"1995","unstructured":"Persico AM, Schindler CW, Zaczek R, Brannock MT, Uhl GR (1995) Brain transcription factor gene expression, neurotransmitter levels, and novelty response behaviors: alterations during rat amphetamine withdrawal and following chronic injection stress. Synapse 19:212\u201327","journal-title":"Synapse"},{"key":"1030_CR29","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0893-133X(99)00092-5","volume":"22","author":"F Pollier","year":"2000","unstructured":"Pollier F, Sarre S, Aguerre S, Ebinger G, Mormede P, Michotte Y, Chaouloff F (2000) Serotonin reuptake inhibition by citalopram in rat strains differing for their emotionality. Neuropsychopharmacology 22:64\u201376","journal-title":"Neuropsychopharmacology"},{"key":"1030_CR30","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1097\/00004714-199910001-00002","volume":"19","author":"J Popik","year":"1999","unstructured":"Popik J (1999) Preclinical Pharmacology of Citalopram. J Clin Psychopharmacol 19:S4\u2013S22","journal-title":"J Clin Psychopharmacol"},{"key":"1030_CR31","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0014-2999(03)01272-X","volume":"463","author":"L Prut","year":"2003","unstructured":"Prut L, Belzung C (2003) The open field as a paradigm to measure the effects on anxiety-like behaviours: a review. Eur J Pharmacol 463:3\u201333","journal-title":"Eur J Pharmacol"},{"key":"1030_CR32","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/00002826-200201000-00004","volume":"25","author":"L Rampello","year":"2002","unstructured":"Rampello L, Chiechio S, Raffaele R, Vecchio I, Nicoletti F (2002) The SSRI, citalopram, improves bradykinesia in patients with Parkinson\u2019s disease treated with L-dopa. Clin Neuropharmacol 25:21\u201324","journal-title":"Clin Neuropharmacol"},{"key":"1030_CR33","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/01.fbp.0000186631.53851.71","volume":"17","author":"R Rygula","year":"2006","unstructured":"Rygula R, Abumaria N, Flugge G, Hiemke C, Fuchs E, Ruther E, Havemann-Reinecke U (2006) Citalopram counteracts depressive-like symptoms evoked by chronic social stress in rats. Behav Pharmacol 17:19\u201329","journal-title":"Behav Pharmacol"},{"key":"1030_CR34","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.neubiorev.2004.08.008","volume":"28","author":"Y Sari","year":"2004","unstructured":"Sari Y (2004) Serotonin 1B receptors: from protein to physiological function and behavior. Neurosci Biobehav Rev 28:565\u2013582","journal-title":"Neurosci Biobehav Rev"},{"key":"1030_CR35","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1097\/00001756-199804200-00013","volume":"9","author":"RK Schwarting","year":"1998","unstructured":"Schwarting RK, Thiel CM, Muller CP, Huston JP (1998) Relationship between anxiety and serotonin in the ventral striatum. Neuroreport 9:1025\u20131029","journal-title":"Neuroreport"},{"key":"1030_CR36","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1073\/pnas.052712799","volume":"99","author":"P Svenningsson","year":"2002","unstructured":"Svenningsson P, Tzavara ET, Witkin JM, Fienberg AA, Nomikos GG, Greengard P (2002) Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac). Proc Natl Acad Sci 99:3182\u20133187","journal-title":"Proc Natl Acad Sci"},{"key":"1030_CR37","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/00001756-199902250-00034","volume":"10","author":"H Tanaka","year":"1999","unstructured":"Tanaka H, Kannari K, Maeda T, Tomiyama M, Suda T, Matsunaga M (1999) Role of serotonergic neurons in L-DOPA-drvied extracellular dopamine in the striatum of 6-OHDA-lesioned rats. Neuroreport 10:631\u2013634","journal-title":"Neuroreport"},{"key":"1030_CR38","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00221-005-2240-y","volume":"164","author":"M Torras-Garcia","year":"2005","unstructured":"Torras-Garcia M, Costa-Miserachs D, Coll-Andreu M, Portell-Cortes I (2005) Decreased anxiety levels related to aging. Exp Brain Res 164:177\u2013184","journal-title":"Exp Brain Res"},{"key":"1030_CR39","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1006\/nbdi.2002.0499","volume":"10","author":"C Winkler","year":"2002","unstructured":"Winkler C, Kirik D, Bjorklund A, Cenci MA (2002) L-dopa-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of Parkinson\u2019s disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis 10:165\u2013186","journal-title":"Neurobiol Dis"},{"key":"1030_CR40","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0891-0618(93)90023-W","volume":"6","author":"M Zoli","year":"1993","unstructured":"Zoli M, Ferraguti F, Toffano G, Fuxe K, Agnati LF (1993) Neurochemical alterations but not nerve cell loss in aged rat neostriatum. J Chem Neuroanat 6:131\u2013145","journal-title":"J Chem Neuroanat"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-007-1030-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-007-1030-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-007-1030-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T16:06:33Z","timestamp":1558627593000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-007-1030-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12,23]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["1030"],"URL":"https:\/\/doi.org\/10.1007\/s00213-007-1030-6","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,12,23]]}}}